Would you consider using daratumumab in the first line setting for non-transplant eligible multiple myeloma?

Agree as above; you cannot fairly compare PFS when the treatment arms have different durations of therapy.

One could argue that the current standard for previously untreated elderly myeloma patients is continuous lenalidomide and dexamethasone, as described in the FIRST study, (Benboubker et al, NEJM...

Let's wait for the MAIA data to come out, but Dara will likely be moving in for the TI MM folks in combos that are more relevant for the US practice soon.

I would, the Dara combination for the recurrent populations are outstanding and there is no reason added to VRD it should not improve the outcomes

The MRD- rate in these studies are very impressive, and it appears that MRD- at less than 1 in a million equals to a high proportion of continued remiss...

I will be careful to identify those who are ineligible for transplant. Regarding the ALCYONE trial (daratumumab/melphalan/bortezomib/prednisone) is not applicable in the USA because we rarely use PO melphalan upfront. My number 1 option to treat this group of pts is VRD per the SWOG S0777, as it sho...

My biggest challenge here after identifying that the person is not transplant eligible is identifying who should be on doublet vs triplet! As for a clear reason the patient was not transplant eligible. In another world what is the scenario where you will use only rd?